UAE Hypersomnia Therapeutics Market Analysis

UAE Hypersomnia Therapeutics Market Analysis


$ 3999

The UAE Hypersomnia Therapeutics Market was valued at $41.83 Mn in 2023 and is predicted to grow at a CAGR of 7.50% from 2023 to 2030, to $69.39 Mn by 2030. The key drivers of this industry include the rising prevalence of sleep disorders, expanding geriatric population, early detection, and advancement in diagnostic tools. The key players in the industry are Teva, Jazz Pharmaceuticals, and Neopharma among others.

ID: IN10AEPH576 CATEGORY: Pharmaceuticals GEOGRAPHY: UAE AUTHOR: Avantika Gupta

Buy Now

UAE Hypersomnia Therapeutics Market Executive Summary

The UAE Hypersomnia Therapeutics Market is at around $41.83 Mn in 2023 and is projected to reach $69.39 Mn in 2030, exhibiting a CAGR of 7.5% during the forecast period.

Hypersomnia is a group of neurological disorders characterized by excessive daytime sleepiness, despite getting enough sleep at night. This can significantly impair daily functioning and reduce quality of life. While the exact causes are still being researched, hypersomnia can be linked to underlying medical conditions, neurological disorders, or disruptions in sleep regulation mechanisms. People with hypersomnia often experience symptoms such as not feeling refreshed upon waking, feeling groggy and slow for extended periods after waking, and an excessive need for sleep despite sleeping for long periods. Chronic headaches, loss of appetite, excessive sweating, and depression have also been reported. Treatment for hypersomnia focuses on managing daytime sleepiness. This can involve adopting healthy lifestyle practices like eating well and exercising regularly. Medications like stimulants can also be prescribed to promote wakefulness. In some cases, cognitive behavioral therapy for insomnia (CBT-I) can help address underlying sleep habits that contribute to hypersomnia.

The prevalence of hypersomnia in UAE is estimated to be around 0.5 to 5% of the general population. The market therefore is driven by significant factors like the increasing awareness about hypersomnia disorders, rising prevalence, and advances in sleep disorder research. However, high costs of treatment, limited accessibility to specialized healthcare services, and strict regulatory approval restrict growth of the market

Since there is no cure for hypersomnia, treatment currently focuses on managing symptoms, particularly excessive daytime sleepiness. The leading pharmaceutical companies include Teva Pharmaceuticals for the treatment of hypersomnia disorders in UAE. Sahara Pharmaceuticals, BIOPROJET, and Neopharma are also significant contributors to the hypersomnia therapeutics landscape, with continuous research and development activities.

UAE Hypersomnia Therapeutics Market Report 2023 to 2030

Market Dynamics

Market Growth Drivers

Increasing Awareness about Hypersomnia Disorders: Increased public awareness campaigns and healthcare professional education are leading to more accurate diagnoses, raising the potential patient pool for these medications. Dubai Hospital has held a campaign to help improve public knowledge about the signs, symptoms, complications, diagnosis, and treatment options for sleep problems.

Expanding Geriatric Population: Hypersomnia may be more common among elderly individuals, as a result of alterations in sleep patterns and existing health issues. Given that the geriatric demographic makes up 2% of the population, the incidence of hypersomnia disorders is projected to increase, leading to a greater need for specialized treatment approaches designed specifically for older adults.

Advances in Sleep Disorder Research: Advances in sleep disorder research and the development of new treatments, such as multiple sleep latency tests (MSLT), are enhancing the accuracy of hypersomnia diagnosis, leading to increased demand for treatment.

Market Restraints

High costs of treatment: The costs associated with the development and commercialization of hypersomnia drugs are significant. This financial burden restricts access to these medications, particularly in a healthcare system where coverage may be limited for certain treatments, making it difficult for patients to afford long-term therapy

Strict Regulatory Approval Process: The regulatory framework for pharmaceuticals in the UAE is stringent, requiring extensive testing and compliance with guidelines set by authorities such as the Ministry of Health and Prevention (MOHAP). This leads to delays in the approval and availability of new hypersomnia treatments, limiting market access to innovative therapies

Limited Accessibility to Specialized Healthcare Services: Sleep disorder clinics, neurologists, and sleep medicine specialists are difficult to access in some regions, including rural ones. Untimely diagnosis, inappropriate treatment, and insufficient ongoing care for individuals with hypersomnia cause underdiagnosis and undertreatment of the condition.

Regulatory Landscape and Reimbursement Scenario

The regulatory landscape for pharmaceuticals in UAE is governed primarily by the UAE Ministry of Health and Prevention (MOHAP). The regulatory framework is designed to ensure the safety, efficacy, and quality of pharmaceutical products available in the market. Before a pharmaceutical product can be marketed and sold in the UAE, it must undergo a rigorous registration process with MOHAP. It also regulates pharmaceutical prices in the UAE.

To seek drug approval, an electronic application is submitted for the drug's registration. MOHAP's technical committees then meticulously review the application and all submitted documents. After the technical review, the committees make recommendations that are forwarded to a ministerial committee for final approval.

In Abu Dhabi, Thiqa is the mandatory health insurance plan for their residents. It offers comprehensive coverage for in-patient and out-patient care at government healthcare facilities. For treatment outside the emirate, Thiqa reimburses 50% of the cost. Dubai's mandatory health insurance plan provides coverage for essential healthcare services at designated DHA facilities. There are different coverage tiers available, allowing residents to choose a plan that meets their needs and budget

Competitive Landscape

Key Players

Here are some of the major key players in the UAE Hypersomnia Therapeutics Market:

  • Teva Pharmaceuticals
  • Jazz Pharmaceuticals
  • Johnson & Johnson
  • Al Hayat Pharmaceuticals
  • Sahara Pharmaceuticals
  • BIOPROJET
  • Merck
  • Neopharma
  • NewBridge Pharmaceuticals Ltd.
  • Roche
  • GlaxoSmithKline
  • Theranexus

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

UAE Hypersomnia Therapeutics Market Segmentation

By Application

  • Idiopathic Hypersomnia
  • Narcolepsy Type-1
  • Narcolepsy Type-2

By Product

  • Anti-depressants
  • Stimulants
  • Sodium oxybate
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.​

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

  • Analyzing historical proprietary data collected from multiple projects.
  • Regularly updating our existing data sets with new findings and trends.
  • Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

  • Searching through academic conferences, published research, citations, and social media platforms
  • Collecting and compiling diverse data to build a comprehensive and detailed database
  • Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

  • Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
  • Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
  • Continuously refreshing our database to ensure that the information remains current and reliable.
  • Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

  • Merging historical data from secondary research with real-time data from primary research.
  • Conducting thorough data validation and cleansing to remove inconsistencies and errors.
  • Organizing data into a structured format that is easily accessible and usable for various applications.
  • Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


Last updated on: 12 September 2024
Updated by: Dhruv Joshi

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up